SBIR/STTR Research Award
A Culture-Free Platform for Rapid Pathogen Identification
Award amount
$299,310Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HELIXBIND, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- C37HLWKKAH69
- Solicitation number
- PA10-123
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): A Culture-Free Platform for Rapid Pathogen Identification Project Summary Sepsis is a one of the leading causes of morbidity and mortality in the US, with more than 751,000 confirmed cases occurring every year and 210,000 mortalities. This high mortality rate (~30%) means that nearly 600 patients a day succumb to sepsis-related infections. In addition to the human toll, the economic burden is likewise immense, reaching 24B/year in the US, with an average cost of over 23,000 per patient. The key to treating sepsis properly is rapid and accurate identification of the causative microorganism (bacterial or fungal). Unfortunately, given the wide range of potential pathogens which can induce sepsis, the 'gold-standard' todayfor diagnosis remains culturing; which typically requires up to 3-5 days for accurate identification leading to a significant delay in the initiation of a targeted treatment protocol. The objective of this Small Business Innovation Research Phase I p
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- An automated culture-free system for the identification of bloodstream infections direct from blood
- Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.
- Direct-from-specimen identification of pathogens common in endocarditis
- Diagnostic tool for assessment and tracking of microbial load in bloodstream infections
- Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
21 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $43,121,128. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation